In Brief: Palomar Medical
This article was originally published in The Gray Sheet
Executive Summary
Palomar Medical: Plans to record a $23 mil. restructuring charge "in addition to an estimated $14 mil. operating loss for the third quarter," the firm states Sept. 30. The charge, which is related to the firm's plans to "focus operations in the cosmetic laser core business," includes $21 mil. in "non-cash charges" and consists of: $11 mil. in "write-offs of outside investments in non-core businesses"; $7 mil. "in reserves against assets in Palomar's non-core subsidiaries"; $3 mil. in reserves "against divesting a start-up overseas subsidiary and restructuring core business operations"; and a $2 mil. reserve for "severance costs associated with consolidating...selling, general and administrative functions, which includes the closing of certain facilities"...
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.